FAP and ovarian adenocarcinoma: Baum et al. [45] retrospectively evaluated the cyclic FAP-binding radioligand in 11 patients with metastatic adenocarcinomas (pancreatic adenocarcinoma (n = 5); breast adenocarcinoma (n = 4); ovarian adenocarcinoma (n = 1) and rectal adenocarcinoma (n = 1)).